U.S. Wireless Telecom Stock News

Partner trial for Darzalex Faspro using Halozyme's ENHANZE technology reported significant survival benefits for multiple myeloma patients. Late stage study results point to improved outcomes for people receiving this subcutaneous therapy. News is material for Halozyme Therapeutics (NasdaqGS:HALO) as it relates directly to one of its key partnered medicines. Halozyme Therapeutics centers its business on ENHANZE, a drug delivery technology licensed to large biopharma partners. The latest...

Visteon (NasdaqGS:VC) has entered new multi year partnership agreements to secure advanced memory and storage supplies for automotive applications. The company is part of Micron's newly completed Strategic Customer Agreements alongside other major automotive suppliers and partners. The partnerships focus on long term supply and technology planning for next generation, AI enabled vehicle platforms. Visteon sits at the intersection of automotive electronics and software, supplying cockpit...

Greenbrier Companies stock has delivered a 37.0% total return over the past 5 years, yet the latest valuation checks point to a mixed picture rather than a clear bargain or clear premium at the current US$50.02 share price. Over 5 years, a 37.0% return suggests Greenbrier Companies has rewarded patient shareholders, which naturally raises the bar for fresh upside from here. Future demand for railcars and related services can support earnings and cash flow, while any pressure on manufacturing...

ACI Worldwide stock has surged over the past three years, yet the valuation picture is mixed, with the intrinsic value estimate from a Discounted Cash Flow (DCF) model suggesting the shares trade below that estimate while the broader checks still do not flag the stock as a clear bargain. ACI Worldwide has returned 150.3% over the past three years, which puts extra focus on whether the current price still leaves room above intrinsic value or mainly reflects past gains. Recent news...

After a very strong three year share price run of 277.6%, Bank of New York Mellon Corporation now faces a valuation debate, with its intrinsic value estimate from the Excess Returns model pointing to the stock trading at a premium, while market multiples suggest pricing that is closer to about right. BNY has delivered a very large 277.6% total return over three years, which means a lot of optimism is already reflected in the share price. Recent earnings momentum, supported by fees, interest...

Peoples Bancorp stock has delivered a 77.3% return over the past 5 years. At a last close of US$39.39, the Excess Returns intrinsic value estimate still points to meaningful upside, while the market multiples suggest the shares are priced roughly in line with peers. Over 5 years, a 77.3% total return suggests the market has already repriced Peoples Bancorp materially higher, so the easy gains may be behind it. Future profitability and loan growth can support the current valuation, but...

Prologis (PLD) kicked off its Q2 2026 update with revenue of about US$2.4 billion and basic EPS of roughly US$1.11 for the quarter, alongside trailing twelve month earnings growth of 22.1% and a net margin of 43.8%. Over the past six quarters, the company has seen revenue move from about US$2.21 billion in Q1 2025 to roughly US$2.43 billion in Q2 2026, with trailing twelve month revenue reaching about US$9.6 billion and basic EPS of around US$4.52. For investors, the combination of higher...

Powell Industries has delivered an exceptionally strong long term share price return over the past five years, yet its current valuation checks lean expensive rather than cheap. Powell Industries has returned about 25x over the last five years, which puts extra focus on whether the current share price already reflects investors' expectations. Growing interest in power infrastructure for data centers can support elevated expectations for future earnings, but recent pressure on the share price...

Ionis Pharmaceuticals (NasdaqGS:IONS) has dosed the first participant in the Phase 1-2 ASCEND trial of ION337 for Dravet syndrome. The study marks the first clinical evaluation of ION337, a next generation RNA targeted therapy candidate. ION337 has FDA Fast Track designation for Dravet syndrome, a rare seizure disorder with no approved disease modifying treatments. For investors following Ionis Pharmaceuticals, this new trial adds a fresh data point to the company’s rare disease portfolio...

Texas Capital Bancshares has delivered a 68.2% return over the past five years, yet the current valuation picture is mixed, with the Excess Returns intrinsic value estimate indicating the stock may trade below its estimated worth while market multiples sit closer to about right. A 68.2% return over five years points to a stock that has already rewarded patient shareholders, so the question is how much valuation upside may still be on the table. The appointment of Mo Jamous as Chief Digital...

Mattel stock has had a tough run over the past three years, yet its current valuation checks lean cheap, which sets up a clear tension between weak long term returns and a market price that screens as potentially modestly undervalued. Mattel has declined 32.5% over the past three years, which means today’s valuation is being judged against a share price that has already come down meaningfully. On the upside, UBS has highlighted Mattel’s broad brand portfolio as a source of brand equity that...

Ecolab stock has delivered a 48.8% total return over the past three years, and at around US$272.83 per share the key question is whether that run now leaves it trading close to its intrinsic value or at a premium. The Discounted Cash Flow (DCF) estimate points to Ecolab being roughly fairly valued, while the broader valuation checks and market multiples lean more cautious. Ecolab's 48.8% return over three years means anyone who stayed invested has been rewarded, so fresh buyers now need to...

Resideo Technologies has nearly doubled investors' money over the past three years, and the current valuation checks suggest the stock still trades at a discount, with the Discounted Cash Flow (DCF) intrinsic value estimate indicating room above the recent US$35.83 share price. Resideo Technologies has returned 98.4% over the past three years, which puts extra focus on whether that gain is fully backed by fundamentals. The planned spin off of the ADI Global Distribution business may support...

Voter support is tilting toward democratic socialist policies like universal healthcare, higher taxes on the wealthy, and more government-backed services, and that puts parts of the healthcare sector squarely under the spotlight. For investors, the bigger question is how potential future reforms and tougher oversight could affect margins, pricing power, and long term business models. This article examines the political catalysts behind this shift and then outlines 3 healthcare stocks that...

Ameris Bancorp (ABCB) heads into its next earnings report on July 23 with expectations for higher year over year earnings and revenue, putting fresh attention on how the stock prices in those forecasts. See our latest analysis for Ameris Bancorp. The recent 7 day share price return of 2.10% and 30 day share price return of 7.32% suggest momentum has been building in Ameris Bancorp ahead of its earnings update. At the same time, the 1 year total shareholder return of 38.48% and 3 year total...

Target Hospitality stock has delivered a very large 359.6% total return over the past five years, yet the current valuation checks lean expensive, with a low overall value score and market multiples that screen as overvalued. A 359.6% five year return means long term shareholders have already seen substantial gains, so fresh buyers are coming in after a strong run. Future contract wins and utilization levels can support earnings and cash flow, but any disappointment in occupancy or pricing...

Trump Media & Technology Group’s plan to charge up to US$100,000 per month for high speed API access to President Trump’s Truth Social posts is turning market information itself into a premium product. When a single message can jolt the S&P 500, oil prices, or individual stocks, the gap between traders who see that data first and everyone else can matter. This article looks at three stocks exposed to this new pay to see model, with one potentially positioned on the right side of the trend and...

Sticky inflation, a firm jobs market, and a Federal Reserve that signals it may keep policy tight or even tighten further all put a spotlight on companies tied to AI infrastructure and data centers. Capital spending linked to AI could both support earnings potential and add fresh inflation pressure, so stock selection matters. This article looks at how those macro forces intersect with AI related demand, and highlights three stocks with positive exposure from our AI Infrastructure and Data...

CAVA Group stock has given investors a solid 41.1% gain over the past three years, yet the latest valuation checks and recent share price pullback raise questions about whether the current level still makes sense or now leans expensive. Over the past three years, CAVA Group has returned 41.1%. This puts the recent share price weakness into context as a pause after a stronger multi year run. The planned expansion of the restaurant base can support higher revenue expectations over time. The...

WaFd (WAFD) has put up a clean set of Q3 2026 numbers, with total revenue of about US$194.5 million and basic EPS of roughly US$0.85 feeding into trailing 12 month revenue of about US$761.1 million and EPS of around US$3.17. The company has seen revenue move from about US$721.1 million on a trailing basis in Q3 2025 to roughly US$761.1 million by Q3 2026, while trailing EPS shifted from about US$2.62 to US$3.17, setting the backdrop for investors weighing slower top line growth against firmer...

Leadership transition at Napco Security Technologies Napco Security Technologies (NSSC) has announced a leadership transition that shifts founder Richard Soloway from Chief Executive Officer to Founder and Executive Chairman, while long-time executive Kevin Buchel steps into the Chief Executive Officer and President roles. For investors watching Napco Security Technologies stock, the move concentrates day-to-day operational responsibility with Buchel, who has more than 25 years of experience...

Rayonier (NYSE:RYN) has appointed Ryan Daniels as Senior Vice President, Wood Products. Daniels steps into the permanent role after serving as Interim SVP, Wood Products. He previously held operational roles at PotlatchDeltic before its recent merger with Rayonier. Rayonier, trading at about $21.8 per share, is in the middle of integrating its wood products operations following its merger with PotlatchDeltic. The appointment of Ryan Daniels formalizes leadership over one of the company’s...

After a strong three year gain of 107.1%, Hanover Insurance Group no longer looks obviously cheap, and the current checks point to a stock that is priced roughly in line with its fundamentals rather than at a clear bargain. Over the past 3 years, Hanover Insurance Group has returned 107.1%, which puts extra attention on whether recent share price strength is already baking in much of the good news. The recently announced CEO succession plan can support confidence in continuity and execution...

Catalyst Pharmaceuticals stock has delivered a very large 5 year return, yet the latest valuation checks suggest the current price looks roughly in line with what the broader fundamentals support rather than clearly cheap or clearly stretched. Over the past 5 years, Catalyst Pharmaceuticals has returned about 4.6x, which puts extra focus on whether the recent share price now simply reflects the progress already made. The agreed acquisition by Angelini Pharma can support confidence in the...